Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Other
Dantrolene is a direct-acting skeletal muscle relaxant used to treat chronic spasticity and life-threatening malignant hyperthermia by inhibiting calcium release in muscle cells.
Name
Dantrolene
Raw Name
DANTROLENE SODIUM
Category
Other
Salt Form
Sodium
Drug Count
5
Variant Count
25
Last Verified
February 17, 2026
RxCUI
856652, 856656, 856660, 856696, 856698, 1544753, 1544758, 1012465, 856654, 856658, 856662
UNII
287M0347EV
About Dantrolene
Dantrolene is a direct-acting skeletal muscle relaxant used to treat chronic spasticity and life-threatening malignant hyperthermia by inhibiting calcium release in muscle cells.
Detailed information about Dantrolene
References used for this content
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Dantrolene.
Originally FDA-approved in 1974 for the management of chronic spasticity and later in 1979 for the treatment of malignant hyperthermia, dantrolene remains a cornerstone in critical care and rehabilitative medicine. Its primary clinical utility is divided into two distinct areas: the long-term management of clinical spasticity resulting from upper motor neuron disorders (such as spinal cord injury, stroke, cerebral palsy, or multiple sclerosis) and the emergency treatment of malignant hyperthermia (a rare but fatal hypermetabolic reaction to certain anesthetic gases).
Healthcare providers view dantrolene as a 'rescue medication' in the context of anesthesia, where it is the only specific antidote for malignant hyperthermia. In chronic settings, it is often reserved for patients whose spasticity significantly interferes with their daily functioning or nursing care, particularly when other treatments have failed or are not tolerated.
To understand how dantrolene works, one must understand the process of muscle contraction. Normally, when a nerve signal reaches a muscle, it triggers the release of calcium ions from a storage site within the muscle cell called the sarcoplasmic reticulum. This flood of calcium allows the muscle filaments to slide past each other, resulting in a contraction.
At the molecular level, dantrolene works by binding to the ryanodine receptor 1 (RyR1), which is the primary channel responsible for releasing calcium from the sarcoplasmic reticulum in skeletal muscle. By inhibiting this release, dantrolene effectively 'uncouples' the electrical signal from the physical contraction. The result is a decrease in muscle responsiveness to stimuli, which reduces the force of muscle contractions and alleviates the excessive muscle tightness (spasticity) seen in various neurological conditions.
Crucially, dantrolene is relatively selective for skeletal muscle. While it can affect cardiac and smooth muscle at very high concentrations, at therapeutic doses, it has little to no effect on the heart or the muscles lining the digestive tract. This selectivity is what makes it a vital tool in treating skeletal muscle disorders without causing significant cardiovascular collapse.
The behavior of dantrolene within the human body is complex and requires careful monitoring by healthcare professionals.
Dantrolene is FDA-approved for several critical indications:
Dantrolene is available in several formulations to suit different clinical needs:
> Important: Only your healthcare provider can determine if Dantrolene is right for your specific condition. This medication requires strict medical supervision, particularly due to the risk of liver toxicity.
Dosage for dantrolene is highly individualized and must be titrated (gradually adjusted) by a healthcare provider to find the lowest effective dose that improves function without causing excessive muscle weakness.
For adults, the typical starting dose is 25 mg once daily for seven days. If the patient tolerates this well, the dose is increased to 25 mg three times daily for another seven days. This gradual increase continues according to the following schedule:
The maximum recommended dose for chronic spasticity is 400 mg per day, divided into four doses. If no clinical benefit is observed at the maximum dose after 45 days, the medication is usually discontinued.
The intravenous dose for an active MH crisis starts at 2.5 mg/kg of body weight. This is administered rapidly and may be repeated until the symptoms (high fever, rapid heart rate, muscle rigidity) subside. In some extreme cases, cumulative doses up to 10 mg/kg may be necessary.
Dantrolene is approved for use in children for both spasticity and malignant hyperthermia.
The titration schedule is similar to adults but based on body weight:
The maximum pediatric dose is typically 100 mg four times daily (400 mg/day).
While dantrolene is excreted by the kidneys, no specific dosage adjustment is typically required for patients with renal impairment. However, clinicians should exercise caution as the drug's metabolites may accumulate.
Dantrolene is contraindicated in patients with active hepatic disease, such as hepatitis or cirrhosis. Because of the high risk of drug-induced hepatotoxicity (liver damage), any degree of liver dysfunction requires extreme caution and frequent monitoring of liver enzymes (ALT, AST, and Bilirubin).
Geriatric patients should be started at the lowest end of the dosing range. They are at higher risk for muscle weakness and falls, and they may have age-related declines in liver function that slow the metabolism of the drug.
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not 'double up' on doses to catch up, as this increases the risk of acute muscle weakness and liver toxicity.
Signs of a dantrolene overdose include severe muscle weakness, extreme drowsiness, dizziness, nausea, vomiting, and in severe cases, respiratory depression (slowed breathing) or coma.
In the event of an overdose, contact emergency services or a poison control center immediately. Treatment is primarily supportive, including gastric lavage (stomach pumping) if the ingestion was recent, and monitoring of vital signs and respiratory function.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop taking the medication without medical guidance, as sudden changes can cause a return of severe spasticity.
Most patients taking dantrolene will experience some level of side effects, particularly during the initial titration phase. These often include:
> Warning: Stop taking Dantrolene and call your doctor immediately if you experience any of these serious symptoms:
With prolonged use, the most significant concern is cumulative damage to the liver. Chronic therapy requires regular blood tests to ensure liver enzymes remain within normal limits. Some patients may also develop chronic pleural effusions (fluid in the chest) or persistent gastrointestinal changes. There is also a risk of permanent muscle atrophy (wasting) if the drug causes such profound weakness that the patient becomes completely immobile.
Dantrolene sodium has a potential for hepatotoxicity. Fatalities have been reported. The risk of hepatic injury appears to be greater in females, in patients over 35 years of age, and in patients taking other medications concurrently (especially estrogens).
Report any unusual symptoms, especially those related to liver function or extreme weakness, to your healthcare provider immediately.
Dantrolene is a high-alert medication due to its potential for severe liver injury. It should only be used when the benefits of treating spasticity outweigh the risks of liver damage. Patients must be committed to regular laboratory monitoring and must be able to recognize the early signs of liver dysfunction.
As noted in the side effects section, the FDA has issued a Black Box Warning for Dantrolene Sodium regarding Hepatotoxicity. This warning emphasizes that the drug can cause symptomatic hepatitis (both fatal and non-fatal). The risk is highest in women, patients over 35, and those on high doses (400 mg/day or more). Because of this, the drug should be used at the lowest effective dose for the shortest period necessary.
Patients on chronic dantrolene therapy must undergo the following monitoring:
Dantrolene frequently causes drowsiness, dizziness, and blurred vision. These effects are most pronounced when starting the drug or increasing the dose. Patients should not drive, operate heavy machinery, or engage in hazardous activities until they are certain the medication does not impair their ability to do so safely.
Alcohol should be strictly avoided while taking dantrolene. Alcohol is a central nervous system (CNS) depressant and will significantly increase the sedative effects of dantrolene, leading to extreme drowsiness and an increased risk of respiratory depression or falls.
Dantrolene should not be stopped abruptly if it has been taken for a long period. Doing so can cause a 'rebound' effect, where spasticity returns more severely than before, potentially leading to pain or loss of function. If the drug must be stopped (unless due to acute liver toxicity), the dose should be tapered down slowly under a doctor's supervision.
> Important: Discuss all your medical conditions, especially liver, lung, or heart disease, with your healthcare provider before starting Dantrolene.
For each major interaction, the mechanism usually involves either additive CNS depression or additive stress on the liver's metabolic capacity. Management typically involves dose adjustment, increased monitoring frequency, or choosing alternative therapies.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers.
Dantrolene must NEVER be used in the following circumstances:
These conditions require a careful risk-benefit analysis by a healthcare provider:
There is no known cross-sensitivity between dantrolene and other common muscle relaxants or hydantoin anticonvulsants. However, patients who are sensitive to other drugs in the hydantoin family (like phenytoin) should be monitored more closely for skin reactions.
> Important: Your healthcare provider will evaluate your complete medical history, including your liver health and functional needs, before prescribing Dantrolene.
Dantrolene is classified as FDA Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in humans. Dantrolene is known to cross the placenta.
In the case of Malignant Hyperthermia (a life-threatening emergency), dantrolene should be used regardless of pregnancy status. For chronic spasticity, it should only be used if the potential benefit justifies the potential risk to the fetus. Use near the end of pregnancy may result in 'floppy infant syndrome,' characterized by muscle weakness in the newborn.
Dantrolene is excreted in human breast milk. Because of the potential for serious adverse reactions in nursing infants (including sedation and muscle weakness), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Generally, breastfeeding is not recommended while taking chronic oral dantrolene.
Dantrolene is approved for use in children to treat both spasticity and malignant hyperthermia. However, long-term safety data regarding growth and development are limited. Children should be monitored closely for the same side effects as adults, particularly liver toxicity and excessive weakness that might interfere with motor skill development.
Clinical studies of dantrolene did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects. However, general clinical experience suggests that elderly patients are more susceptible to the sedative effects and the risk of falls due to muscle weakness. Furthermore, because the risk of hepatotoxicity increases with age (especially over 35), the elderly are at a significantly higher risk for liver complications. Dosing should be cautious, starting at the low end of the range.
While the kidneys are not the primary route of metabolism, the metabolites of dantrolene are excreted renally. In patients with significant renal impairment or end-stage renal disease (ESRD), these metabolites may accumulate. While no specific dose reduction is mandated by the FDA, healthcare providers often monitor these patients more frequently for signs of toxicity.
As previously stated, dantrolene is strictly contraindicated in patients with active hepatic disease. In patients with mild, stable hepatic impairment, the drug is rarely used, and if it is, it requires daily or weekly monitoring of liver enzymes. The risk of triggering acute liver failure in this population is exceptionally high.
> Important: Special populations require individualized medical assessment and more frequent laboratory monitoring.
Dantrolene is a post-synaptic skeletal muscle relaxant. Its primary molecular target is the ryanodine receptor 1 (RyR1) located on the sarcoplasmic reticulum of skeletal muscle cells. In a normal muscle contraction, an action potential travels down the T-tubules, triggering the RyR1 to open and release stored calcium (Ca2+) into the cytosol. This calcium binds to troponin C, allowing actin-myosin cross-bridging and contraction.
Dantrolene acts as an antagonist to the RyR1 channel. By binding to the receptor, it reduces the amount of calcium released from the sarcoplasmic reticulum. This decreases the intracellular calcium concentration, which in turn reduces the strength of the muscle contraction. Because it acts directly on the muscle fiber rather than the nerves, it is effective in treating spasticity of both spinal and cerebral origin.
The onset of action for oral dantrolene is slow, with peak effects on spasticity often taking a week or more of consistent dosing to become apparent. In contrast, the IV form used for malignant hyperthermia has a near-immediate onset. The duration of effect for a single oral dose is approximately 6 to 12 hours. There is a clear dose-response relationship, but the therapeutic window is narrow; too little drug is ineffective, while too much causes profound, functional weakness.
| Parameter | Value |
|---|---|
| Bioavailability | ~70% (Oral) |
| Protein Binding | ~90% (Primarily to Albumin) |
| Half-life | 8-9 hours (Oral); 4-8 hours (IV) |
| Tmax | 3-6 hours |
| Metabolism | Hepatic (Hydroxylation/Reduction) |
| Excretion | Renal (25%), Fecal (Remainder via Bile) |
Dantrolene is the only member of the direct-acting skeletal muscle relaxant class. It is distinct from centrally acting agents (like cyclobenzaprine) and GABA-agonists (like baclofen). It is also distinct from neuromuscular blocking agents (like vecuronium) used in surgery, as it does not block the nicotinic receptors at the neuromuscular junction.
Medications containing this ingredient
Common questions about Dantrolene
Dantrolene is primarily used for two distinct medical purposes: the management of chronic muscle spasticity and the treatment of malignant hyperthermia. For spasticity, it helps patients with conditions like multiple sclerosis, cerebral palsy, or spinal cord injuries by reducing excessive muscle tightness and spasms. In the case of malignant hyperthermia, it is a life-saving emergency medication used to stop a fatal reaction to certain anesthesia gases. It works directly on the muscle fibers rather than the brain or spinal cord. Your healthcare provider will determine if its benefits for your movement outweigh its potential risks.
The most common side effects of dantrolene include significant drowsiness, dizziness, and muscle weakness. Many patients also report feeling generally tired or unwell, especially when first starting the medication or during a dose increase. Gastrointestinal issues such as diarrhea, nausea, and stomach cramps are also frequently observed. These side effects often decrease in intensity as your body becomes accustomed to the drug over several weeks. However, if muscle weakness makes it difficult to perform daily tasks or breathe, you should contact your doctor immediately.
No, you should strictly avoid drinking alcohol while taking dantrolene. Both alcohol and dantrolene can cause significant drowsiness and slow down the central nervous system. Combining them can lead to extreme sedation, impaired coordination, and an increased risk of dangerous falls or accidents. Furthermore, alcohol can put additional stress on the liver, which is already at risk of damage from dantrolene. To ensure your safety and protect your liver health, it is best to eliminate alcohol consumption entirely during treatment.
Dantrolene is classified as Pregnancy Category C, meaning its safety in human pregnancy has not been fully established. Animal studies have shown potential risks to the fetus, and the drug is known to cross the placenta. In life-threatening emergencies like malignant hyperthermia, the drug is used because the benefit to the mother's life is paramount. For chronic spasticity, however, doctors usually only prescribe it if the benefits clearly outweigh the risks to the developing baby. If you are pregnant or planning to become pregnant, a detailed discussion with your specialist is necessary.
The time it takes for dantrolene to work depends on the condition being treated and the method of administration. When given intravenously for an emergency like malignant hyperthermia, it begins working almost immediately to lower body temperature and relax muscles. For chronic spasticity treated with oral capsules, the effects are much slower to appear. It often takes a week of consistent dosing to notice an improvement, and the full therapeutic benefit may not be realized for several weeks as the dose is gradually increased. Your doctor will monitor your progress to find the optimal dose.
You should not stop taking dantrolene suddenly unless your doctor specifically tells you to, especially if you have been taking it for a long time. Abruptly stopping the medication can cause a 'rebound' effect, where your muscle spasticity returns quickly and potentially more severely than before. This can lead to increased pain, stiffness, and loss of mobility. If the medication needs to be discontinued, your healthcare provider will typically provide a tapering schedule to slowly reduce the dose. The only exception is if you show signs of acute liver toxicity, in which case immediate discontinuation is required.
If you miss a dose of dantrolene, you should take it as soon as you remember. However, if it is nearly time for your next scheduled dose, you should skip the missed dose and simply take the next one at the regular time. Never take two doses at once to make up for a missed one, as this can increase the risk of severe muscle weakness and other side effects. Maintaining a consistent schedule helps keep the medication at a steady level in your body. If you frequently forget doses, consider using a pill organizer or setting a phone alarm.
Weight gain is not a commonly reported side effect of dantrolene. In fact, some patients may experience a slight weight loss due to side effects like nausea, loss of appetite, or diarrhea. However, because dantrolene can cause significant muscle weakness and fatigue, some patients may become less physically active, which could indirectly lead to weight changes over time. If you notice significant or rapid changes in your weight while taking this medication, you should discuss them with your healthcare provider to rule out other underlying causes or fluid retention.
Dantrolene can interact with several other medications, some of which are very serious. It should not be used with certain calcium channel blockers like verapamil, as this can cause heart problems. It also has increased risks when taken with estrogens (like birth control) or other drugs that can damage the liver. Because it causes drowsiness, taking it with other sedatives, sleep aids, or strong pain medications can be dangerous. Always provide your doctor and pharmacist with a complete list of all medications and supplements you are taking to avoid harmful interactions.
Yes, dantrolene sodium is available as a generic medication in both capsule and injectable forms. The generic version is typically more cost-effective than the brand-name versions like Dantrium or Ryanodex. Generic medications are required by the FDA to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug. If you are concerned about the cost of your medication, ask your doctor or pharmacist if the generic version of dantrolene is an appropriate and available option for your specific treatment plan.